Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

Cancer discovery·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer.

Biomarker research·2026
Same author

Metabolic vulnerabilities in pleural mesothelioma.

Oncogenesis·2026
Same author

Liquid Biopsy in Advanced Prostate Cancer.

Cancers·2026

相关实验视频

Updated: Jan 18, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

最小残留疾病增强了可切除非小细胞肺癌病理反应之外的预后分层.

Mariano Provencio1, Roberto Serna-Blasco1, Ernest Nadal2

  • 1Hospital Universitario Puerta de Hierro Majadahonda Majadahonda, Madrid Spain.

Clinical cancer research : an official journal of the American Association for Cancer Research
|January 15, 2026
PubMed
概括

在手术后检测最小残留疾病 (MRD) 可以提高可切除非小细胞肺癌 (NSCLC) 预后的准确性,而非小细胞肺癌 (NSCLC) 则需要接受外科手术期间的化疗免疫治疗. 阴性MRD状态表明生存率有利,即使在没有病理完整反应的患者中也是如此.

更多相关视频

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

493
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

相关实验视频

Last Updated: Jan 18, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

493
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

科学领域:

  • 在瘤学瘤学.
  • 翻译研究是翻译研究.
  • 分子诊断学 分子诊断学

背景情况:

  • 在外科手术期间的化学免疫疗法是可切除的非小细胞肺癌 (NSCLC) 的标准.
  • 病理完整反应 (pCR) 预测了生存,但一些非pCR患者获得了长期的结果.
  • 最小残留疾病 (MRD) 评估可能会提供更精细的预后见解.

研究的目的:

  • 评估可切除NSCLC的患者中最小残留疾病 (MRD) 的预后附加值.
  • 为了确定MRD状态是否精细化了病理完整反应 (pCR) 以外的预后.

主要方法:

  • 在60名来自NADIM II试验的NSCLC患者中,使用Gardant Reveal试验评估了MRD.
  • 患者接受了新辅助药尼沃卢马布加上化疗或单独化疗,随后进行手术.
  • 辅助性尼沃卢马布 (nivolumab) 用于R0切除的实验手臂患者.

主要成果:

  • 在9.6%的患者中检测到MRD.
  • 手术后或治疗期间的MRD与较低的无事件存活率 (EFS) 和整体存活率 (OS) 相关.
  • 在两个时间点的MRD阴性预测了生存率,并且与明显较低的复发率相关,即使是在非pCR患者中.

结论:

  • 对MRD的评估可以提高可切除NSCLC的预后分层.
  • 在接受外科手术期间化学免疫治疗的患者中,MRD提供了超越PCR的宝贵预后信息.
  • 阳性MRD状态是有利结果的强有力的指标.